CD47 and neoplasm: Consistently, our data also showed that anti-CD47 antibodies (including BC31M4, BC31M5 and Hu5F9) monotherapy did not confer antitumor activity in the syngeneic mouse tumor models although they conferred potent antitumor activity in xenograft models.